Imagene AI was founded in 2020 with a clear mission to empower physicians and researchers with immediate oncology intelligence to facilitate optimal treatment for more cancer patients.
Harnessing the power of biopsy images to unlock groundbreaking insights, we are transforming cancer diagnostics and research with AI-powered precision oncology.
LungOI, the first AI-based NSCLC biomarker test, provides rapid and accurate biomarker profiling, facilitating timely and informed clinical decisions.
Imagene was recognized by Frost & Sullivan for the 2023 "Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis" and won the 2023 Digital Health Award for "Best use of AI." Our success derives from our cutting-edge technology and a multidisciplinary team of data scientists, biologists, software engineers, and medical experts.